The development of guidelines is one of the core activities of the European Society for Medical Oncology (ESMO) and European Society of Gynaecologial Oncology (ESGO), as part of the mission of both societies to improve the quality of care for patients with cancer across Europe. ESMO and ESGO jointly developed clinically relevant and evidence-based recommendations in several selected areas in order to improve the quality of care for women with ovarian cancer. The ESMO–ESGO consensus conference on ovarian cancer was held on April 12–14, 2018 in Milan, Italy, and comprised a multidisciplinary panel of 40 leading experts in the management of ovarian cancer. Before the conference, the expert panel worked on five clinically relevant questions regarding ovarian cancer relating to each of the following four areas: pathology and molecular biology, early-stage and borderline tumours, advanced stage disease and recurrent disease. Relevant scientific literature, as identified using a systematic search, was reviewed in advance. During the consensus conference, the panel developed recommendations for each specific question and a consensus was reached. The recommendations presented here are thus based on the best available evidence and expert agreement. This article presents the recommendations of this ESMO–ESGO consensus conference, together with a summary of evidence supporting each recommendation.
- ovarian cancer
- adjuvant treatment
- molecular biology
- recurrent disease
Statistics from Altmetric.com
Funding All costs relating to the consensus conference were covered from ESMO and ESGO funds. There was no external funding of the event or manuscript production.
Disclaimer These consensus statements were developed by the European Society for Medical Oncology (ESMO) and the European Society of Gynaecological Oncology (ESGO) and are published jointly in the Annals of Oncology and the International Journal of Gynecological Cancer. The two societies nominated participants who attended the consensus conference and co-authored the final manuscript.
DISCLOSURE NCol has reported advisory roles for Roche, PharmaMar, AstraZeneca Clovis, Tesaro, Pfizer, Takeda and Biocad and speaker’s honoraria from Roche, PharmaMar, AstraZeneca and Tesaro; CS has reported advisory board for Clovis; AdB has reported advisory boards and/or lectures (without being member of a speakers’ bureau) for Roche, AstraZeneca, Pfizer, Tesaro, Clovis, BioCad and Genmab/Seattle Genetics; JL has reported research grants from AstraZeneca and MSD/Merck, speaker’s bureau from AstraZeneca and Clovis Oncology and advisory boards for AstraZeneca, Pfizer, Clovis Oncology, Tesaro and Merck/MSD; IMN has reported advisory roles for AstraZeneca, Clovis, Tesaro and Takeda; SP has received honoraria from Roche, AstraZeneca, Clovis, Tesaro, MSD and Pfizer and reported research funding from Roche; IRC has reported conducting clinical studies sponsored by AstraZeneca and Roche; IV has reported advisory boards for Advaxis Inc., Eisai Inc., MSD Belgium, Roche NV, Genmab A/S, Genmab US, F. Hoffmann-La Roche Ltd, PharmaMar, Millennium Pharmaceuticals, Clovis Oncology Inc., AstraZeneca NV, Tesaro Bio GmbH, Tesaro Inc., Oncoinvent AS, Immunogen Inc. and conducting research sponsored by Amgen and Roche; TB has reported research grant from Amgen, travel expenses from Amgen and Roche and advisory board membership for Tesaro; SB has reported educational grants, advisory boards, travel expenses and/or lectures for AstraZeneca, Clovis, Gamamabs, Merck, PharmaMar, Seattle Genetics, Roche, Tesaro and Janssen-Cilag; PB has received honoraria for lectures and written opinions from Roche Polska and AstraZeneca Polska; NCon has reported funding for travel, accommodations and expenses from Roche, Genmab and Amgen and consulting or advisory role with Seattle Genetics and AstraZeneca; RG has reported consultancy/advisory boards for AstraZeneca, Tesaro, Clovis, Sotio, Roche and Immunogen; research funding from Lilly/Ignyta, Boehringer Ingelheim and Roche; expenses to attend meetings from AstraZeneca, Tesaro and Roche and participation in research sponsored by AstraZeneca, Tesaro, Clovis, Immunogen and Pfizer; AGM has reported that he is a member of advisory boards for AstraZeneca, Clovis, Tesaro, Roche, PharmaMar, Immunogen, Genmab, Pfizer/Merck and MSD and speaker’s fees for Roche, AstraZeneca, Tesaro and PharmaMar; FJ has reported advisory boards, travel expenses and lectures for Tesaro and AstraZeneca; FK has reported educational grants from PharmaMar; DL has reported advisory boards for AstraZeneca, Merck, Clovis and Tesaro and institutional research support from PharmaMar and Clovis; SM has reported research support, advisory board, honoraria and travel expenses from AstraZeneca, Clovis, Medac, MSD, Novartis, PharmaMar, Roche, Sensor Kinesis, Tesaro and Teva; MRM has reported links (not specified) with Advaxis, AstraZeneca, Boehringer Ingelheim, Clovis Oncology, Genmab, Karyopharm, Novocure, Pfizer, Roche, Seattle Genetics, Tesaro, Oncology and Sera Prognostics; SN has reported advisory boards for Roche, Tesaro, AstraZeneca and Clovis and research funding from AstraZeneca; DOD has received financial support for travel and accommodation costs from AstraZeneca; PP has reported conducting a clinical study sponsored by PharmaMar; JS has reported advisory boards and lectures for PharmaMar, AstraZeneca, Clovis, Roche and Tesaro; DSPT has reported conducting research sponsored by Roche, AstraZeneca and Pfizer, receiving research funding by AstraZeneca and received honoraria from Roche and AstraZeneca; WGMC, PM, IB, AD, SO, FP, DQ, IB, DC, NC, BD, MDS, AF, VHS, JWK, MM, AR, FS, NS, DT, GT, JvdV, POW and AZ have reported no conflicts of interest.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.